Quick Asked: Synchrogenix, A Certara Company Contact Us?
Last update: 19 Apr, 2024 
241 Views
Why certcertara synchrogenix? Certara Synchrogenix assures and accelerates the approval of and access to medical innovations through a unique combination of customized regulatory strategy, document authoring, medical communications and publications, and operations solutions.What can you do at certara? Working alongside smart and driven colleagues, you can help advance smarter model-informed drug development, expedite regulatory submissions and approvals, and expand market access. Learn more about jobs at Certara.Why choose synchrogenix for document review? About us. Synchrogenix provides clients with objective, professional document review services. Our rigorous quality-control process includes checks of data, formatting, spelling, grammar, and clarity. Our team includes industry experts, medical doctors, and clinicians who provide our clients with objective content review.Why certara for drug discovery? The drug discovery and development process is long and expensive with more failures than successes. At Certara, we anticipate and address your critical drug discovery and development risks and decisions using biosimulation and tech-enabled services.
Listing Results Synchrogenix, A Certara Company Contact Us? Question Answers
Certara Accelerating Medicines with Biosimulation and
Certara is the global leader in biosimulation. Since 2014, our customers, who use our software and tech-enabled services, have received 90% of drug and biologic approvals by the FDA. We accelerate medicines by optimizing R&D productivity through model-informed drug development, regulatory science, and market access solutions. Our clients include 1,650+ global ...
Europe Medical Writing Market Astonishing Growth in 2020 with
The Europe medical writing market is expected to reach US$ 1,114.92 million in 2027 from US$ 655.84 million in 2019. The market is estimated to grow with a CAGR of 6.9% from 2020-2027.
SYNCHROGENIX EUROPE LIMITED Officers (free information
SYNCHROGENIX EUROPE LIMITED - Free company information from Companies House including registered office address, filing history, accounts, annual return, officers, charges, business activity C/O Certara, 100 Overlook Center, Suite 101, Princeton, New Jersey, United States, 08540 United States Of America Occupation Private Equity
Bob Bowden Director, Information Techno.. Certara
View Bob Bowden's business profile as Director, Information Technology at Certara. Find contact's direct phone number, email address, work history, and more.
Synchrogenix Opens New Office in Northern New Jersey
About Synchrogenix, a Certara™ Company. Synchrogenix, a Certara™ company, encompasses a group of separate entities operating together to provide regulatory writing services to the
Certara buys Synchrogenix with its eye on regulatory
Certara, an informatics-focused pharma contractor, has bought up specialty CRO Synchrogenix, absorbing a company devoted to regulatory writing with hopes of expanding its market share. Under the
» Patient Centricity Synchrogenix
Patient Engagement and Patient Centricity Series Part III: Engaging with The Right Patients for the Right Purpose. Nirpal Virdee, Synchrogenix’s Global Head of Transparency and Disclosure recently sat down with Trishna Bharadia, award-winning health advocate and patient engagement champion, for a discussion around patient engagement and patient centricity.
Registration Scientific Webinar Series Certara
The impact of alterations in GFR, protein binding, and TDIs on PK predictions for the OCT2 model substrate, metformin. The utility of available in vitro data to improve predictions of renal clearance for OCT2 substrates in clinical RI populations.